TEMALIEVA 20 mg contains Temozolomide, an oral alkylating chemotherapy agent. It works by methylating DNA, leading to DNA damage and apoptosis of rapidly dividing tumor cells. Temozolomide readily crosses the blood–brain barrier, making it especially effective for brain tumors.

Temozolomide is indicated for treatment of:

1.  Glioblastoma multiforme (GBM)
     – Newly diagnosed (with radiotherapy) and recurrent disease

2.  Anaplastic astrocytoma

3.  Other high-grade gliomas (off-label, as per protocol)

Common side effects:

•   Nausea and vomiting

•   Fatigue

•   Constipation or diarrhea

•   Headache

•   Loss of appetite

Hematological side effects:

•   Thrombocytopenia

•   Neutropenia

•   Anemia

Serious side effects:

•   Severe myelosuppression

•   Opportunistic infections (e.g., Pneumocystis jirovecii pneumonia)

•   Liver enzyme elevation

Regular CBC and liver function monitoring is required.

Dosage depends on body surface area (BSA) and treatment phase.

Common regimens:

1. Concomitant with radiotherapy (GBM):

  •   75 mg/m² once daily for 42 days

2.  Maintenance / Adjuvant therapy:

  •    150–200 mg/m² once daily for 5 days every 28 days

 20 mg capsules are used for dose titration and adjustment.


NOTE: This medicine should be taken only under a doctor’s supervision.